Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32748
Title: | Total Chemical Synthesis of Palmitoyl-Conjugated Insulin. | Austin Authors: | Liu, Mengjie;Li, Qingyang;Delaine, Carlie;Wu, Hongkang;Arsenakis, Yanni;White, Barbara F;Forbes, Briony E;Chandrashekar, Chaitra;Hossain, Mohammed Akhter | Affiliation: | Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia.;The Florey Institute of Neuroscience and Mental Health, Parkville 3052, Australia. The Florey Institute of Neuroscience and Mental Health Discipline of Medical Biochemistry, College of Medicine and Public Health, Flinders University, Adelaide, South Australia 5042, Australia. Medicine (University of Melbourne) Discipline of Medical Biochemistry, College of Medicine and Public Health, Flinders University, Adelaide, South Australia 5042, Australia. School of Chemistry, and Department of Biochemistry and Pharmacology, The University of Melbourne, Victoria 3010, Australia. |
Issue Date: | 18-Apr-2023 | Date: | 2023 | Publication information: | ACS Omega 2023; 8(15) | Abstract: | Commercially available insulins are manufactured by recombinant methods for the treatment of diabetes. Long-acting insulin drugs (e.g., detemir and degludec) are obtained by fatty acid conjugation at LysB29 ε-amine of insulin via acid-amide coupling. There are three amine groups in insulin, and they all react with fatty acids in alkaline conditions. Due to the lack of selectivity, such conjugation reactions produce non-desired byproducts. We designed and chemically synthesized a novel thiol-insulin scaffold (CysB29-insulin II), by replacing the LysB29 residue in insulin with the CysB29 residue. Then, we conjugated a fatty acid moiety (palmitic acid, C16) to CysB29-insulin II by a highly efficient and selective thiol-maleimide conjugation reaction. We obtained the target peptide (palmitoyl-insulin) rapidly within 5 min without significant byproducts. The palmitoyl-insulin is shown to be structurally similar to insulin and biologically active both in vitro and in vivo. Importantly, unlike native insulin, palmitoyl-insulin is slow and long-acting. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32748 | DOI: | 10.1021/acsomega.2c07918 | ORCID: | 0000-0003-4360-9927 0000-0002-0288-5952 0000-0002-9961-0006 |
Journal: | ACS Omega | Start page: | 13715 | End page: | 13720 | PubMed URL: | 37091377 | ISSN: | 2470-1343 | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.